Continuing anti-TNF treatment with CZP for RA during pregnancy: No or negligible placental transfer

(European League Against Rheumatism) The results of a pharmacokinetic study presented today at the Annual European Congress of Rheumatology 2017 showed no or negligible placental transfer of the anti-TNF drug certolizumab pegol from mothers to infants during pregnancy.